PF-08634404

PF-08634404 (SSGJ-707) is an investigational agent whose form is not stated in the registry developed by Pfizer and Sunshine Guojian Pharmaceutical (Shanghai). Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 13 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07222800 (Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer), NCT07392892 (Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer) and NCT07226999 (Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer), in colorectal cancer, gastric & gastro-oesophageal junction cancer, oesophageal cancer, non-small-cell lung cancer and bladder & urothelial cancer. The largest, NCT07222566, plans to enrol 1410 participants with primary completion expected 2029-02-27. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.